The proposed methodology will be used to identify ASPS-specific genetic signatures from i) patient microarray readouts using tissue biopsy samples of primary and metastatic tumors of alveolar soft part sarcoma (ASPS) [17], ii) an immortalized cell line developed from a lymph node metastasis of one patient [16], and iii) biopsy-derived RT-PCR data from the ASPL-TFE3 fusion transcript used in the diagnosis of this disease. The gene discussed is TFE3; the disease is alveolar soft part sarcoma.